obesity drug news today october 21 2025 glp-1 Outlook for in 2025: more than a transition year GLP-1 Genetics: How Genes Affect

In the main per-protocol analyses, mean follow-up was 483 days in the GLP-1RA and 397 days in the SGLT-2i group

However, wider use of GLP-1RAs early in disease progression may provide superior glycaemic control and weight loss, and therefore result in more favourable long-term outcomes

doi: 10.3389/fphar.2024.1397029, 60

Users should view it as a wellness supplement rather than a medication replacement

Instead, contact your PlexusDx provider to discuss officially delaying your next dose increase or temporarily reducing your dose

The litigation is called: MDL -3163 IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation